Introduction
A virus receptor is defined as an entity on the cell surface to which a virus specifically binds. A consequence of this interaction is internalization and entry into the susceptible host cell. The first retroviral receptor to be identified as a predefined cell surface molecule was that utilized by the human and simian immunodeficiency viruses (HIV-1, HIV-2 and SIV) (Dalgleish et al., 1984; Klatzmann et al., 1984; Sattentau et al., 1988) . HIV, in common with the majority of other retroviruses studied, enters cells following binding to CD4 by fusing the viral envelope and cellular plasma membrane at physiological pH (pH-independent entry) (Stein et al., 1987; McClure et al., 1988 McClure et al., , 1990 .
Confirmation that CD4 served as the principal receptor for HIV was achieved following transfection of the human CD4 gene into human HeLa cells. HeLa cells expressing human CD4 acquired susceptibility to infection (Maddon et al., 1986) . Interestingly, murine 3T3 cells transfected with human CD4 allowed only HIV binding but not the subsequent steps of membrane fusion permitting entry. This provided the first evidence that binding to CD4 alone was not sufficient and that the * Author for correspondence. Fax +47 55 544512. e-mail maja, Sommerfelt @ rmf.uib.no participation of other cell surface molecules, described as co-receptors or cofactors, was required to complete the entry process.
HIV co-receptors appear to be expressed on the majority of human and primate, but not rodent and nonprimate cells (Tersmette et al., 1989; Clapham et al., 1991 ; Dragic et al., 1992; Broder et al., 1993; Harrington & Geballe, 1993) . Despite utilizing CD4 as their principal receptor, HIV-1, HIV-2 and SIV exhibit subtle differences in tropism suggesting that they have the capacity to exploit distinct molecules as co-receptors (Clapham et al., 1991 ; Dragic & Alizon, 1993) .
In order to identify potential HIV-1 co-receptors, investigators have exploited the observation that HIV, in common with many retroviruses, has the ability to induce cell-to-cell fusion resulting in the formation of multinucleate giant cells termed syncytia (Fig. 1 a) when infected and uninfected cells are mixed together (Dalgleish et al., 1984; Braun et al., 1994) . Syncytium induction occurs as a result of interactions between viral envelope glycoproteins and virus-specific cell surface receptors since this effect can be inhibited using antibodies directed against virus receptors or neutralizing antibodies directed against viral envelope glycoproteins (Dalgleish et al., 1984) .
The leukocyte function antigen 1 (LFA-1, i.e. CD18/ CD 11 a) has been implicated in HIV-1-induced syncytium formation and entry (Hildreth & Orentas, 1989 ; Goud- (Table 2) or the control anti-CD4 antibody Q4120. These antibodies inhibited syncytium formation without dispersing the cell aggregates. Bar markers represent 400 lam.
smit & Smit, 1990; Valentin et al., 1990; Panteleo et al., 1991) . Since antibodies that inhibited syncytium formation did not inhibit HIV-1 entry, LFA-1 has been disregarded as a putative HIV co-receptor for mediating virus entry. However, the potential involvement of LFA-1 in the fusion of LFA-l-expressing cells remains (Panteleo et al., 1991 ; Golding et al., 1992) . In efforts to identify further candidate HIV coreceptors, a panel of monoclonal antibodies (MAbs) directed against a variety of adhesion molecules was tested for the ability of the MAbs to inhibit HIV-1-induced cell fusion. All the MAbs directed against a particular antigen for which some inhibition was observed were subsequently tested for their ability to inhibit HIV-1 entry. Entry was assayed using vesicular stomatitis virus (VSV) pseudotype viruses which represent a phenotypic virus mixture, where the core and genome are provided by the unrelated rhabdovirus VSV and the envelope glycoproteins are donated by HIV. These pseudotype viruses acquire the receptor host range and entry characteristics of the virus donating the envelope glycoproteins. The VSV pseudotype technique has been applied to a wide range of retroviruses including HIV . It is particularly useful as a rapid and quantitative means to study virus receptors since it assays specifically virus binding and entry independently of later steps in the virus life cycle.
We have identified antibodies to cell surface molecules other than CD4 which nevertheless have significant effects on syncytium induction and/or HIV-1 entry. We present evidence suggesting that certain epitopes of the intercellular adhesion molecule 3 (ICAM-3), a molecule not previously implicated as an HIV co-receptor, may play a role in the entry of HIV-1 into lymphoid and monocytoid cells.
Methods
Viruses and cells. Human SupT1 and CEM cells (provided by Dr F. Barr6-Sinoussi, Pasteur Institute, France) were grown in RPMI 1640 medium supplemented with 10 % fetal bovine serum (FBS), denoted 10% RPMI. Mink CCL64 (Henderson et al., 1974) and human HeLa-CD4 ceils (Akrigg et al., 1991) were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10 % FBS.
The HIVLa 1 laboratory-adapted strain of HIV-1 provided by Dr F. Barrr-Sinoussi at a reverse transcriptase activity titre of 885000 c.p.m./ml was used to infect CEM cells. An equivalent of 5000 c.p.m, was used to infect 10 x 106 CEM cells in a volume of 200 gl 10% RPMI. After incubation for 1 h at 37 °C, the cells were washed twice and diluted to 1 x 10 ~ cells/ml. The cells were incubated at 37 °C with 5 % CO 2 and passaged at least twice before being used in the syncytial assays. The supernatant, harvested as a stock for infectivity assays, had a p24 value of 2 gg/ml and a TCID~0 value of 5 x 104 on SupT1 cells, and was stored at -135 °C.
Wild-type VSV Indiana strain was a gift from Dr Miklos Degr~ (University of Oslo, Norway).
Antibodies. A panel of 166MAbs directed against adhesion molecules were provided by the Vth International Conference and Workshop on Human Leukocyte Differentiation Antigens as ascites fluids. A control purified antibody directed against human CD4, Q4120 (Healey et al., 1990) , was also provided by the workshop. All antibodies were initially tested at a final ascites dilution of 1:100 and a final concentration of 20 gg/ml for the control Q4120.
Syncytium inhibition assay. Syncytium inhibition assays were carried out as described by Clapham et aL (1991) . Briefly, 50 gl SupT1 cells (at 106 cells/ml) were preincubated for 30 min at 37 °C with 50 gl ofa 1:50 dilution of ascites fluid in 96-well trays (giving a final ascites dilution of 1:100) or 50 gl of control anti-CD4 antibody Q4120 giving a final concentration of 20 gg/ml. Then 50 gl CEM cells chronically infected with HIV~a 1 were added (at 106 cells/ml). After overnight incubation syncytium induction was scored using light microscopy.
Pseudoo'pe assay. Pseudotype viruses were generated by superinfecting chronically HIV-l-infected CEM cells with wild-type VSV at an m.o.i, of 10 p.f.u./cell in a cell density of 10 n cells/0'2 ml serum-free medium. Following virus adsorption for 1 h at 37 °C, non-adsorbed VSV was washed away by centrifugation and the cells were finally resuspended in growth medium (10% RPMI) at a density of 2 × 106 cells/ml and incubated at 37 °C for 15 h. The supernatant was harvested, clarified by centrifugation (2000 r.p.m, for 10 min in a Beckman tabletop centrifuge) and stored at -135 °C. The fraction of virus corresponding to wild-type VSV was neutralized initially using a goat anti-VSV polyclonal antibody kindly provided by Dr R. A. Weiss (Institute of Cancer Research, London, UK) and later using a polyclonal anti-VSV antibody raised in rabbits (Animal Unit, Haukeland Hospital, Bergen, Norway). Non-neutralized VSV, corresponding to pseudotype viruses bearing HIV-1 envelope glycoproteins, denoted VSV(HIV) were titrated on SupT1 cells as described by Clapham et al. (199l) . Briefly, neutralized VSV was plated onto 5 x 106 SupT1 cells immobilized onto poly-L-lysine-coated 6-well trays. Following adsorption of virus for 1 h at 37 °C, the inoculum was removed and the cells were overlaid with 106 mink cells (resistant to HIV-1) to enhance the visualization of plaques. When the mink cells had settled, the medium was removed and the cells were overlaid with 10 % RPMI containing a final concentration of 0.6 % Difco Bacto-Agar. The stock of VSV(HIV) used throughout this study had a titre of 2-4 x 104 p.f.u./ml.
Inhibition assays using MAbs were carried out by preincubating the SupT1 ceils with 200 gl ascites fluid at a dilution of 1:50 in serum-free medium before adding 200 gl pseudotype virus inoculum containing 100-150 p.f.u. (a countable number, just less than confluence).
Infectivity assay. SupT1 cells were seeded in a 96-well tray in a volume of 50 gl (106 cells/ml) and preincubated with a 1:50 dilution of ascites fluid for 30 min at 37 °C. Control anti-CD4 antibody was used at a final concentration of 20 gg/ml. SupT1 cells were infected with 25 TCIDr0 units of the HIVe, stock (corresponding to 0-I ng p24) for 2 h at 37 °C. The cells were then washed three times in serum-free medium and finally resuspended in 100 lal 10% RPMI containing a 1:100 final dilution of ascites fluid. Supernatant was harvested from the cells 6 days post-infection and the levels of extracellular p24 were monitored as described by Sundqvist et al. (1989) .
Results

Syncytium inhibition assay
A total of 166 distinct MAbs were tested for their ability to inhibit HIV-1-induced cell fusion as described. Table  1 lists the antigens recognized by antibodies that failed to inhibit HIV-l-induced syncytium formation at a final ascites dilution of 1:100 where the control anti-CD4 antibody Q4120 was effective. Figure l(a) represents syncytium formation resulting from overnight co-cultivation of CEM cells chronically infected with HIVL~ i and uninfected SupT1 target cells either in the absence of antibody or in the presence of an antibody that does not inhibit syncytium formation. Only one antibody to VLA-1 partially inhibited syncytium formation (50% reduction in syncytium formation), but none of the antibodies to VLA-1 had any effect on the entry of VSV(HIV) pseudotype viruses.
As shown in Table 2 , significant inhibition of syncytium formation was observed with one antibody against CD18, one against CD1 lb, one against CDllc and one against CD50 (ICAM-3). Fig. 1 (b) is representative of the inhibition of syncytium formation produced by these antibodies and the control against CD4. None of the antibodies that inhibited syncytium formation dispersed the cells preventing cell contact. This phenomenon has previously been reported for certain antibodies to CD18 not included in our panel (Valentin et al., 1990) .
Only one antibody (S121) out of a total of 17 directed against ICAM-3 (CD50) significantly inhibited HIV-1-induced cell fusion. Partial inhibition of syncytium formation was also noted at a 1 : 500 final ascites dilution, showing that this antibody was less inhibitory than the purified control antibody raised against CD4 (Table 2) . To rule out the possibility that antibody S121 was reacting with CD4, we tested the ability of this antibody to inhibit HIV-l-induced cell fusion of HeLa-CD4 cells that do not express ICAM-3. Despite being effective on lymphoid SupT1 cells, antibody S121 failed to inhibit syncytium induction with HeLa-CD4 cells. Interestingly, none of these antibodies to ICAM-3 could inhibit HIV2ro~-induced cell fusion of SupT 1 cells which further rules out the blocking of CD4 as a mechanism for syncytium inhibition by antibody S121 (data not shown). Taken together, these results suggest that the inhibitory effect of antibody S121 was specific for HIV-1 on lymphoid cells.
Inhibition of virus entry
Since there was an inhibitory effect with certain antibodies directed against CD18, CDllb,c, and ICAM-3 (CD50) the entire collection of antibodies directed against these antigens as well as those against CDlla were tested for their ability to inhibit the entry of VSV(HIV) pseudotype viruses bearing HIV-1 envelope glycoproteins. One antibody directed against CD 11 a and one directed against CDllc significantly inhibited the plating of VSV(HIV) pseudotype viruses (by 68 % and 70% respectively) ( Table 2 ). The antibody directed against CDllc that caused a 70% reduction of VSV(HIV) plating was the same antibody that significantly inhibited syncytium induction. None of the antibodies directed against CDlla inhibited syncytium formation and none of the antibodies directed against CD18 or CDllb inhibited the entry of VSV(HIV) pseudotype viruses (Table 2) . I" Antibody S167, named G-25.2. $ Control antibody Q4120 was a purified antibody used at corresponding concentrations of 40 lag, 20 lag, 4 lag and 0.4 lag/ml. Of 17 antibodies directed against ICAM-3, only one (S121) significantly inhibited syncytium formation. This same antibody inhibited the plating of VSV(HIV) pseudotype viruses by up to 90 %, a degree comparable to that of the control antibody directed against CD4 (Tables 3 and 4) . Although the control anti-CD4 antibody did not neutralize VSV(HIV) plating totally, its inhibitory effect on pseudotype plating could be titrated further than for antibody S121 (Table 4) . Seven other antibodies to ICAM-3 significantly inhibited VSV(HIV) pseudotype plating by up to 70 % without having an effect on syncytium formation (Table 3) ; total inhibition was not achieved using these antibodies, not even at ascites dilutions of 1 : 25.
The observed inhibition of VSV(HIV) plating was not restricted to SupT1 cells, since equivalent results were also observed using the U937 and CEM cell lines.
Effect of anti-ICAM-3 antibodies on HIV infectivity
The antibodies directed against ICAM-3 were tested to determine their effect on the infectivity of HIVza i in culture. The antibodies that did not inhibit VSV(HIV) plating similarly had no effect on HIV infectivity on SupT1 cells. For antibodies S109, Sl13, S114 and S121, the inhibition of HIVL~i infectivity was very similar to that of VSV(HIV) pseudotype plating (Table 3) . Table 4 shows that antibody S 121 inhibited HIV infectivity more effectively than the control anti-CD4 antibody at an ascites dilution of 1:5000. The difference between the efficiency of antibody S121 in the pseudotype assay and the infectivity assay at a 1:500 ascites dilution could reflect the higher number of cells used/volume of antibody in the pseudotype assay compared to the infectivity assay.
A discordant pattern was observed for antibodies S093, S108, Sl12 and Sl15 (Table 3 ). Although they inhibited VSV(HIV) plating by up to 70 % they had a marginal effect on HIVL~ j infectivity. The pseudotype assay measures specifically entry in a single round of infection whereas the infectivity assay monitors several round of replication and virus spread in culture over time. The avidity of antibody binding may therefore have been less stable for those antibodies showing a discordant pattern in the infectivity assay. In addition, Table 3 shows that antibodies S108 and Sl15 bind domain 2, S112 binds domains 1 and 2 whereas S093 binds domain 1. In contrast, the majority of antibodies that were inhibitory to both pseudotype plating and infectivity mapped to domain 1 on ICAM-3. Only four antibodies to domain 1 had no effect on HIV entry or infectivity. The precise locations and amino acid sequences of the epitopes recognized by the 17 anti-ICAM-3 antibodies is not presently known.
Discussion
HIV entry and HIV-induced syncytium formation are proving to be complex processes that are poorly understood in precise molecular terms. In an effort to identify candidate HIV-1 co-receptor molecules a panel of 166 MAbs raised against diverse adhesion molecules was initially screened for the ability of the MAbs to inhibit HIV-l-induced cell fusion. A large number of antibodies had no effect on HIV-l-induced cell fusion (Table 1) ; however, this does not exclude these molecules as candidate co-receptors, because insufficient antibodies to each antigen were tested to cover all known epitopes. Indeed, not all epitopes on human CD4 are involved in HIV-induced cell fusion, and it was in this way that the epitope corresponding to the HIV binding site on CD4 was identified (Sattentau et al., 1986) .
This study involved the testing of more antibodies directed against LFA-1 (CD18/CDlla) and CDllb, CDllc than previously described. In agreement with previous results (Golding et al., 1992) a limited number of antibodies had a significant inhibitory effect on cell-tocell fusion without affecting virus entry. Only one antibody raised against CDIla inhibited virus entry alone (Table 2) . Previous studies have shown these molecules to be more relevant in the process of cell-tocell fusion (syncytium formation) rather than in the fusion of viral and cellular membranes during virus entry (Goudsmith & Smit, 1990; Panteleo et al., 1991) .
The processes of cell-to-cell fusion and fusion between viral and cellular membranes may involve the participation of distinct components in addition to CD4. This hypothesis is supported by the fact that cell-to-cell fusion does not always reflect virus-cell fusion (infection) since some cell lines, e.g. RC2-A (Valentin et al., 1994) and a subline of U937 (Collman et al., 1989) will not undergo cell-to-cell fusion despite being susceptible to HIV infection. Furthermore, certain epitopes on CD4 have been reported to be involved in HIV-induced syncytium formation but not entry (Corbeau et al., 1993) showing that these processes are also not identical regarding their involvement of CD4. The syncytial assay is a highly qualitative assay, since different target cell lines vary in the number and extent of syncytia produced in response to HIV. We have now identified antibodies that can distinguish between the two assays, for example by inhibiting cell-to-cell fusion but not virus entry and vice versa, emphasizing that these two processes, although involving membrane fusion, are not identical.
The results of this study provide the first evidence suggesting an involvement of ICAM-3 in HIV entry. One antibody to ICAM-3 (S121) significantly inhibited not only syncytium induction, but also the entry of VSV(HIV) pseudotype viruses and the infectivity of HIVL~ ~ (Tables 2, 3 and 4) . The effect of S121 on syncytium induction was specific for HIV-1 on lymphoid cells since HIV-l-induced cell fusion of HeLa-42D4 cells was not affected and nor was syncytium formation induced by HIV-2ro d on SupT1 cells (data not shown). Interestingly, an additional seven MAbs raised against ICAM-3 significantly inhibited the entry of VSV(HIV) pseudotype viruses without affecting syncytium formation. This inhibition of pseudotype plating was also observed on CEM (T cell) and U937 (monocytoid) cells. The discordant effect noted for the four antibodies that significantly inhibited entry but not infectivity could reflect differences in the avidity of antibody binding to ICAM-3 and the stability of the antigen-antibody complex over time in culture. The majority of antibodies that showed this discrepancy bound domain 2 whereas those that were most effective bound domain 1 (Table 3) . Since more antibodies were identified that affected entry rather than syncytium formation, this suggested that ICAM-3 is more relevant in the process of virus entry than in cell-to-cell fusion (syncytium formation).
The VSV pseudotype assay measured HIV-mediated entry independently of later steps in the HIV replication cycle. Antibody was only present during VSV(HIV) adsorption and replication of VSV then proceeded in the absence of antibody. In contrast, the infectivity assay involved the continued presence of antibody in culture. No antibody inhibited HIV infectivity without inhibiting VSV(HIV) pseudotype plating, although the converse was true. This suggested that the observed inhibition did not result from indirect effects on cell viability or postpenetration HIV replication, but rather from a direct inhibition of virus-receptor interactions.
ICAM-3, a molecule of 120 kDa belonging to the immunoglobulin supergene family, was recently shown to be the same as CD50 (Juan et al., 1993) , and represents the third ligand for LFA-1 (De Fougerolles & Springer, 1992) . It consists of five immunoglobulin-like domains having significant homology to ICAM-1, with the greatest divergence in the cytoplasmic tail (Fawcett et al., 1992; Vazeux et al., 1992; . ICAM-3 is expressed on lymphoid cells, dendritic cells and cells of the monocyte/macrophage lineage, unlike ICAM-1, which is also found on epithelial cells. In this way, ICAM-3 gene expression largely correlates with the in vivo receptor host range of HIV.
The observations that HeLa-CD4 cells, which lack ICAM-3 gene expression, are nevertheless still susceptible to HIV-mediated cell fusion implies that HIV-1 has the capacity to exploit different cell surface molecules on different cell types in order to achieve membrane fusion and entry following binding to CD4 and that the co-receptors for HIV-1 on HeLa-CD4 and SupT1 cells are distinct. This is certainly plausible since HIV can utilize either CD4 (Dalgleish et al., 1984; Maddon et al., 1986) or galactosyl ceramide-mediated entry Harouse et al., 1991; Fantini et al., 1993) depending on host cell type.
Constitutive expression of ICAM-3 on lymphoid cells makes it readily available to interact with HIV-1 on the cell surface in combination with CD4. Unlike ICAM-1, ICAM-3 is not only involved in LFA-l-mediated adhesion but also acts as a signal transducer providing potent co-stimulatory signals that lead to T cell activation following LFA-1 binding (Hernandez-Caselles et al., 1993; Vives, 1994) . It is conceivable that interactions between ICAM-3 and HIV-1 may similarly lead to cellular activation, a feature necessary for HIV replication since LFA-1 binds to the most extracellular domain of ICAM-3 (domain 1) in common with antibodies that significantly inhibited HIV-1-induced cell fusion and entry (Table 3; Klickstein et al., 1993) . ICAM-3 therefore represents an interesting candidate HIV-1 co-receptor worthy of further study to determine its exact role in HIV-1 entry.
